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Caveolin-1 is dispensable for early 
lymphoid development, but plays a role 
in the maintenance of the mature splenic 
microenvironment
Tyler A. Herek1†, Jacob E. Robinson2†, Tayla B. Heavican3, Catalina Amador3, Javeed Iqbal3 
and Christine E. Cutucache2*
Abstract 
Objective: Caveolin-1 (CAV1) is known for its role as both a tumor suppressor and an oncogene, harboring a highly 
context-dependent role within a myriad of malignancies and cell types. In an immunological context, dysregulation 
of CAV1 expression has been shown to alter immunological signaling functions and suggests a pivotal role for CAV1 in 
the facilitation of proper immune responses. Nonetheless, it is still unknown how Cav1-deficiency and heterozygosity 
would impact the development and composition of lymphoid organs in mice. Herein, we investigated the impacts 
of Cav1-dysregulation on the lymphoid organs in young (12 weeks) and aged (36 weeks) Cav1+/+, Cav1+/−, and 
Cav1−/− mice.
Results: We observed that only Cav1-deficiency is associated with persistent splenomegaly at all timepoints. Further-
more, no differences in overall body weight were detected (and without sexual dimorphisms). Both aged Cav1+/− and 
Cav1−/− mice present with decreased  CD19+CD22+ B cells and secondary-follicle atrophy, specifically in the spleen, 
compared with wild-type controls and irrespective of splenomegaly status. Consequently, the demonstrated effects 
on B cell homeostasis and secondary follicle characteristics prompted our investigation into follicle-derived human 
B-cell lymphomas. Our investigation points toward CAV1 as a dysregulated protein in follicle-derived B-cell malignan-
cies without harboring a differential expression between more aggressive and indolent hematological malignancies.
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Introduction
Caveolin-1 (CAV1) is located on chromosome 7q31.2 at 
the D7S522 locus, a fragile point known to be deleted in 
certain human cancers [1]. CAV1 is commonly described 
with a two-faced nature as both a tumor suppressor and 
an oncogene [2]. This paradox is seen across multiple 
malignancies as the expression of CAV1 has been shown 
to be both up- and down-regulated compared to normal 
tissue, with both phenotypes capable of harboring poor 
prognoses [2, 3].
With the “Janus-faced” nature of CAV1, research-
ers have turned to Cav1-deficient mice to sort out the 
heterogeneity. Cav1−/− mice, but not Cav1+/− mice, 
harbor a reduced lifespan in comparison to wild-type 
(WT) controls; however, the reduction in lifespan 
is not due to an increased frequency of tumorigenic 
events [4, 5]. Rather, pulmonary and cardiac compli-
cations drive the observed lifespan reduction [4]. It is 
clear that Cav1 plays a largely context-dependent role, 
with varied phenotypes seen throughout different 
organ systems as well as a progression of these pheno-
types over time. Nonetheless, it is still unknown how 
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Cav1-deficiency and heterozygosity would impact the 
development and composition of the primary and sec-
ondary lymphoid organs of mice. Cav1 is expressed in 
cells of the immune system [6, 7] and plays a vital role 
in not only immune synapse formation [8] but also in 
macrophage-, T-, and B-cell signaling [8–14]. While 
previous studies have investigated Cav1-deficiency in 
terms of B-cell development [10, 14, 15], T-cell devel-
opment [10, 11], and recently the immunophenotype 
of the spleen (SP) and bone marrow (BM) in aged mice 
[14]; no comprehensive study which includes both pri-
mary and secondary lymphoid organs, a longitudinal 
component, and a Cav1-heterozygous experimental 
population exists.
Consequently, herein we investigated the impact of 
Cav1 on the lymphoid organ system. Specifically, we 
addressed how the primary and secondary lymphoid 
organs of mice can be immunophenotypically described 
at a young/non-diseased stage (12 weeks) and how the 
underlying pathologies of Cav1-deficiency impact these 
organs at near end-of-life (36 weeks).
Main text
Results
Caveolin‑1‑deficiency is associated with persistent 
splenomegaly
We observed no statistically significant differences in 
body weight (g) across genotypes and timepoints, with 
no sexual dimorphism (Fig.  1a, Additional file  1: Figure 
S1a). However, as early as 12 weeks, Cav1−/− mice pre-
sented with splenomegaly; a finding consistent across all 
measured timepoints in comparison to WT mice, with 
Cav1+/− mice mirroring WT mice and no observed sex-
ual dimorphism (Fig. 1b, Additional file 1: Figure S1b).
Caveolin‑1 is dispensable for early lymphoid development 
but critical for B cell maintenance in the spleen
Investigating the impact of Cav1-deficiency and 
heterozygosity on B- and T-cell development and 
homeostasis, we observed no statistically significant 
differences in the pre/pro B-cell populations, imma-
ture B-cell populations, or overall  CD19+ B-cell pop-
ulations in the BM nor CD4/CD8 thymic populations 
in all experimental groups and time points (Additional 
Fig. 1 Caveolin-1 deficiency is associated with splenomegaly with implications for Caveolin-1 as haploinsufficient for splenic B-cell maintenance. 
a Line graph of mean body weight (g) of Cav1+/+ (red), Cav1+/− (blue), and Cav1−/− (green) mice at indicated timepoint (n = 9–22 per group). b 
Line graph of mean SP weight (mg) of Cav1+/+ (red), Cav1+/− (blue), and Cav1−/− (green) mice at indicated timepoint (n = 9–15 per group). c (Top 
panel) Dot plots for  CD19+CD22+ B cells in the SP for listed genotypes at 12, 24, and 36 weeks (n = 7–10 per group). (Bottom panel) Representative 
contour flow cytometry plots for  CD19+CD22+ B cells at listed genotypes for listed timepoints. (Line graphs show mean ± SEM, dot plots show 
mean ± SD with each dot corresponding to a biological replicate, flow cytometry gate values show mean ± SEM, NS not significant, *p < 0.05 
ANOVA and Tukey post hoc test)
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file 2: Figure S2a, b). There were no observed changes 
in the resident  CD3+ T-cell populations or skewing 
of the  CD3+CD4+ versus  CD3+CD8+ T-cell popula-
tions in the thymus (Thy), SP, lymph node (LN), or BM 
(Additional file 3: Figure S3a, b). Further, we observed 
no differences in the percentages of mature B cells in 
the LN or BM at 12 or 36 weeks (Additional file 3: Fig-
ure S3c).
Conversely, our aged Cav1−/− and Cav1+/− mice 
exhibited decreased  CD19+CD22+ B-cell percent-
ages in the SP as early as 24  weeks with corrobora-
tive results at 36 weeks (Fig. 1c). Our observation of a 
decrease in splenic B-cell percentages was seen with-
out any concurrent changes to additionally analyzed 
white pulp populations, including: T cells (Additional 
file 3: Figure S3) or myeloid cells (Additional file 4: Fig-
ure S4a–c). With our flow cytometry controlled for cell 
input, events/sample (see “Methods”), and no change 
observed in overall lymphoid percentage (Additional 
file  4: Figure S4d), this excludes the splenomegaly of 
the Cav1-deficient mice as a confounding factor.
Aged Cav1‑transgenic mice exhibit an altered splenic 
microenvironment
In response to the observed dysregulation of splenic 
B-cells in both Cav1−/− and Cav1+/−- mice, we con-
ducted histopathologic analysis on splenic sections 
from all genotypes. Spleens from 12-week mice showed 
no differences under routine examination of H&E sec-
tions (Fig.  2a) with normal splenic architecture, includ-
ing: similar frequency of observable secondary follicles 
(Fig. 2b) as well as mean secondary follicle area (Fig. 2c) 
in accordance with previous observations [10]. How-
ever, at 36 weeks, we noted Cav1−/− and Cav1+/− mice 
to present with fewer secondary follicles (Fig. 2a, b) with 
the observed follicles to be smaller in comparison to age-
matched splenic sections from WT mice (Fig. 2c).
Additional investigation into the proliferative indexes of 
the 36-week sections revealed no statistically significant 
differences in  Ki67+ cells per field of view (Fig. 2d). Utiliz-
ing pentachrome staining we noted an increase in fibrin 
deposits in the spleens of Cav1+/− and Cav1−/− mice 
compared to WT spleens (Fig. 2d). No other investigated 
organs were observed to harbor these deposits. Interest-
ingly, further histopathologic analysis revealed an increase 
Fig. 2 Aged Cav1-transgenic mice exhibit an altered splenic microenvironment. a Representative H&E stained sections of Cav1+/+, Cav1+/−, 
and Cav1−/− spleens at ×4 magnification. b Bar graph of the mean splenic secondary follicle area (μm2) for listed genotypes at 12 and 36 weeks 
(n = 5–10 follicles across n = 2–4 mice per group). c Percentage of observable secondary follicles for listed genotypes at 12 and 36 weeks (n = 2–4 
per group). d Representative Ki67 and Movat’s Pentachrome stained histological sections from 36-week spleens for listed genotypes at 20× 
magnification (n = 3 per group). Increased fibrin staining is visualized in bright red. e Bar graph of mean plasma cells identified per field of view 
(×40) for listed genotypes from 36-week splenic sections (n = 3 per group). (Bar graphs show mean ± SD, with each dot corresponding to a 
biological replicate NS not significant, *p < 0.05 ANOVA and Tukey post hoc test)
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in inter-follicular plasma cells in the spleens of Cav1+/− 
and Cav1−/− mice compared to WT mice (Fig. 2e).
Follicle center B‑cell lymphomas display altered CAV1 
staining and expression patterns
Demonstrated above, we observed Cav1 to play a role 
in the long-term homeostasis of the splenic B-cell pop-
ulation and splenic follicle morphology. We therefore 
became interested in investigating the expression of 
CAV1 in post-secondary follicle B-cell malignancies. To 
this end we scored the Biomax LY6161 tissue microarray 
for CAV1 staining intensity and localization comparing 
healthy lymph node samples to both diffuse B-cell lym-
phoma (DBCL) and follicular lymphoma (FL) samples 
(Fig.  3a). The distribution of staining scores for disease 
entities differed in comparison to the normal LNs with 
fewer B-cell malignancies scored for heavy stromal stain-
ing and an increase in those scored for faint blood/lym-
phatic vessel staining (Fig. 3b). There was no significant 
difference in the distribution of staining scores when 
comparing malignancies. Using publicly available micro-
array data we examined the expression of CAV1 in tumor 
biopsy samples from FL and two established subtypes of 
diffuse large B-cell lymphoma (DLBCL), comparing them 
to normal SP controls. All malignancies analyzed had a 
lower mean expression of CAV1 compared to the healthy 
splenic tissue (Fig. 3c).
Discussion
Herein, we include a characterization of Cav1 in the lym-
phoid compartments of a murine model. Cav1-deficient 
mice exhibited persistent splenomegaly compared to 
Cav1-heterozygous and WT mice. While the mecha-
nism for Cav1-mediated splenomegaly is unknown, we 
ruled out a higher proliferative index as there were no 
differences found in  Ki67+ staining numbers between 
genotypes. Previous investigations found very modest 
or no persistent differences in proliferation/apoptosis in 
Cav1-deficient spleens [5, 9, 14], suggesting a currently 
unresolved physiological condition may be causing the 
phenotype. However, a full knockout of Cav1 is required 
to drive the splenomegaly as our data suggests that Cav1-
heterozygosity is not sufficient to drive the dysregulation 
as splenomegaly was not observed in Cav1+/− mice.
Fig. 3 Follicle center B-cell lymphomas display altered CAV1 staining and expression patterns. a Representative tissue microarray cores stained 
for CAV1 expression. All images taken at ×20. b Bar graph of the distribution of composite scores assigned to healthy LN (n = 26), DBCL (n = 293), 
and FL (n = 18) samples for CAV1 staining. c Boxplot of the normalized log-transformed CAV1 expression value using the 212097_at signal probe 
for SP (n = 12), diffuse large B-cell lymphoma activated B cell-like (DLBCL-ABC) (n = 46), diffuse large B-cell lymphoma germinal center B cell-like 
(DLBCL-GCB) (n = 40), and FL (n = 27). Line within box represents median, whiskers extend to Tukey lines. (For (b): NS not significant, please see 
“Methods” for description of scoring key, *p < 0.05 Kruskal–Wallis and Dunn’s multiple comparisons test. For (c): NS not significant, *p < 0.001 
comparison among groups of arrays method)
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Previous investigations have established CAV1 as vital 
to T-cell function in the context of both antigen presenta-
tion and signal transduction [8, 11–13]. However, we and 
others demonstrate that Cav1 is seemingly dispensable 
for T-cell development and homeostasis [10, 11, 13, 14].
We present data in support of a role for Cav1 in the 
regulation of B-cell processes by observing a decrease in 
B-cell percentages, specifically in the SP, in aged Cav1-
transgenic mice on the C57BL/6 background utilizing 
the knockout method described by Razani et  al. [16]. 
This decrease was seen in conjunction with aberrant 
secondary follicle characteristics in aged mice, however 
a more detailed analysis of these changes is still needed. 
These findings are highlighted with our observation of 
a concurrent decrease in splenic B-cell percentages and 
an increase in inter-follicular plasma cells and fibrin 
deposits in Cav1-deficient and heterozygous mice with-
out both exhibiting splenomegaly. This suggests that 
Cav1-heterozygosity is sufficient to drive the dysregula-
tion of B-cell homeostasis and impair the Cav1-mediated 
internalization of fibrin [17], most likely caused by the 
angiogenic defects observed in Cav1-transgenic mice 
[16]. Further, the observation of increased inter-follicu-
lar plasma cells may elude to a basis for the decrease in 
 CD19+CD22+ (i.e. mature, non-terminally differentiated) 
B cells in Cav1-transgenic mice without additionally per-
turbed populations as plasma cells (mature, terminally 
differentiated) downregulate pan-B surface markers dur-
ing differentiation [18, 19]. Collectively, the decrease of 
mature B cells in conjunction with an increase of fibrin 
deposits and presence of plasma cells indicate that dys-
regulation of Cav1 may induce an inflammatory splenic 
microenvironment.
While there is controversy precise role of Cav1 in B-cell 
signaling, one point of agreement between all published 
reports is that there exists a role for Cav1 in B-cell pro-
cesses as evident by conserved dysregulated responses 
and changes to physiological populations over time 
[14, 15]. However, the lack of consistency in the results 
derived from established Cav1-knockout models calls 
into question how the method and selection of exon as 
well as the genetic background of the mouse contributes 
to the observed results.
Taken together, the data suggests that loss of Cav1 
alone is not sufficient to drive a robust immunological 
phenotype despite its frequent presence as a dysregulated 
molecule in human malignancies. However, Cav1-dys-
regulated cells appear “predisposed” to display aberrant 
signaling profiles given proper stimuli [10, 11, 13–15, 
20–22]. This predisposition, or reprogramming, suggests 
CAV1 as a facilitator of immune/inflammatory-related 
processes and could point toward its ultimate role in the 
progression of multiple human malignancies, including 
both solid tumor [23–25] and hematological diseases 
[8, 26, 27]. To this end, we examined the staining pat-
tern of CAV1 and its expression in follicle-derived B-cell 
malignancies. We observed fainter, less stromal-localized 
CAV1 staining in the hematological malignancies with 
lower CAV1 expression in tumor biopsies compared 
to normal splenic tissue. However, no differences were 
observed between the more aggressive DLBCL cases 
when compared to the more indolent FL cases, not form-
ing a parallel between lowered CAV1 expression being 
associated with a more aggressive disease in both breast 
[23] and prostate cancer [24]. These results suggest that 
CAV1 is dysregulated in follicle-derived B cell malignan-
cies but does not play an overt role between more aggres-
sive and indolent disease entities.
Methods
Flow cytometry
Leukocyte populations were isolated using Lympho Sep-
aration Medium (MP Biomedicals, USA) with red blood 
cells lysed using RBC lysis buffer (Alfa Aesar, USA). Cells 
were counted and checked for viability (> 95%) using 
Trypan Blue (STEMCELL Technologies, CA) and  106 
live cells were aliquoted for antibody staining (Additional 
file  1). Samples were run on a Cytoflex flow cytometer 
(Beckman Coulter, USA) and analyzed using the CytEx-
pert 2.0 software (Beckman Coulter). Compensation was 
calculated utilizing a VersaComp antibody capture bead 
kit (Beckman Coulter). Cells were gated based off for-
ward-side scatter, unstained controls, and fluorescence 
minus one controls. All samples are representative of at 
least 5 × 104 events.
Histology
Animal care protocol found in Additional file  6: Addi-
tional methods. Harvested organs were placed into 10% 
neutral buffered formalin and allowed to fix for ≥ 72  h 
before preservation in 100% ethanol. Preserved tissues 
were paraffin-embedded and sectioned (4 μm). H&E and 
Movat’s pentachrome staining were conducted using 
standard procedures, Ki67 staining using an auto-stain-
ing system.
Histological scoring was conducted for Ki67 stain-
ing, secondary follicle counting, and plasma cell identi-
fication. In each instance, three independent researchers 
scored the relevant variable in 4 separate fields of view 
(n = 3 per genotype). All slides were viewed at identi-
cal magnifications. For scoring agreement metrics and 
follicle area quantification, please see Additional file  5: 
Table S1, Additional file 6: Additional methods.
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TMA scoring
The LY6161 high-density lymphoma and normal lymph 
node tissue array was utilized as previously described 
[27]. Cases were scored for both intensity of stain (faint, 
moderate, heavy) and type of staining observed (vessel 
only, stromal + vessel, or lymphocyte + stromal + vessel). 
Patient characteristics and scoring agreement described 
in Additional file 5: Tables S1, S2.
Gene expression data
(.CEL) files were downloaded via NCBI Gene Expression 
Omnibus and uploaded into BRB-ArrayTools. Samples 
were collated and normalized using the MAS5.0 method. 
Samples described in Additional file 5: Table S3.
Limitations
  • Unresolved splenomegaly in Cav1−/− mice.
  • More in-depth germinal center investigation requires 
additional IHC markers.
  • Higher resolution of B/T-populations could be 
achieved with additional flow markers.
Additional files
Additional file 1: Figure S1. (a) Bar graph of mean body (g) of listed 
genotypes separated by males (no fill pattern) and females (fill pattern) 
(n = 3–9 per group). (b) Bar graph of mean SP weight (mg) of listed 
genotypes separated by males (no fill pattern) and females (fill pattern) 
(n = 2–11 per group). (Bar graphs show mean ± SD with each dot cor-
responding to a biological replicate, NS not significant, * = p < 0.05 ANOVA 
and Tukey post hoc test).
Additional file 2: Figure S2. (a) Dots plots of B-cell populations in the 
BM for Cav1+/+, Cav1+/−, and Cav1−/− mice at 12 and 36 weeks (n = 8–13 
per group). Pre/Pro B cells designated as  CD19+CD22−, immature B 
cells designated as  CD19+CD22+. (b) Representative pseudo-color flow 
cytometry plots of  CD4+ and  CD8+ populations in the Thy at 12 and 
36 weeks for listed genotypes. (c) (Dot plots show mean ± SD with each 
dot corresponding to a biological replicate, flow cytometry gate values 
show mean ± SD).
Additional file 3: Figure S3. (a) Dot plots of  CD3+ T cells in the Thy, 
BM, SP, and LN for listed genotypes at 12 and 36 weeks as determined 
by flow cytometry (n = 7–13 per group). (b) Dot plots of  CD3+CD4+ 
and  CD3+CD8+ T cell populations in the secondary lymphoid organs of 
listed genotype at 12 and 36 weeks (n = 4–9 per group). (c) Dot plots of 
 CD19+CD22+ B cells in the LN for listed genotypes at 12 and 36 weeks 
(n = 8–11 per group). (Dot plots show mean ± SD with each dot cor-
responding to a biological replicate).
Additional file 4: Figure S4. (a) Dot plots of  CD11b+ cells in the SP and 
BM at the listed genotypes for 12 and 36 weeks. (b) Dot plots of  CD14+ 
cells in the SP and BM at the listed genotypes for 12 and 36 weeks. (d) 
Dot plot of splenic lymphocyte percentage in 36-week mice for listed 
genotypes. (Dot plots show mean ± SD with each dot corresponding to a 
biological replicate, NS not significant, * = p < 0.05 ANOVA and Tukey post 
hoc test).
Additional file 5: Table S1. Histological scoring table. Table S2. Patient 
characteristics from the LY6161 high-density lymphoma tissue array. 
Table S3. Publicly available GEO DataSets utilized for gene expression 
analysis. Table S4. Antibodies utilized within the study.
Additional file 6. Animal care and secondary follicle area determination 
methodologies are described.
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